Dosage ; Initial dose: 50mg daily.
Dose adjusted in the increment of 50mg over several weeks
to max. of 200mg daily. Once an optimum response is attained reduce
the dose to usual therapeutic dose of 50-100mg.
Dose of above 150mg should not be given over 8 weeks.
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Inosert | IPCA | Sai Pharmaceuticals Ltd. | 50mg | 28 | Tablet | per tablet | KES 539.00 |
| Inosert | IPCA | Sai Pharmaceuticals Ltd. | 100mg | 28 | Tablet | per tablet | KES 913.00 |
| Serenata- | Torrent Pharmaceuticals Ltd. | Medox Pharmaceuticals Ltd. | 50mg | 30 | Tablet | per tablet | KES 1,500 |
| Serlift | Ranbaxy Laboratories | Pharma Specialities Ltd. | 100mg | 30 | Tablet | per tablet | KES 1,660 |
| Serlin | Zydus Cadila Healthcare | Harley's Limited | 50mg | 50 | Tablet | per tablet | KES 1,500.00 |
| Sertima | Intas Pharmaceuticals Ltd | Unicorn Pharma (K) Ltd. | 50mg | 30 | Tablet | per tablet | KES 1,900.00 |
| Zoloft | Pfizer Global Pharmaceuticals | Surgipharm Ltd | 50mg | 30 | Tablet | per tablet | KES 2,001.00 |
| Zosert | Sunlight International Trading (Africa) Co., Ltd | Harley's Limited | 50mg | 30 | Tablet | per tablet | KES 1,950.00 |
| Serenata-50 | Torrent Pharmaceuticals Ltd. | Medox Pharmaceuticals Ltd. | 50mg | 50 | Tablet | per tablet | KES 1,500.00 |
| Mode Of Action | Combined serotonin (5-HT) and noradrenaline (NA) re-uptake inhibitor e.g. Duloxetine |
|---|---|
| Drug Indication | Depression, obsessive-compulsive disorders, bulimia nervosa. |
| Precautions | Renal / hepatic impairment, withdraw gradually, diabetes, epilepsy, discontinue if seizures develop, elderly, underweight patients as it may lead to massive weight loss, ECT therapy, patients with suicidal tendencies. |
| Contra-Indications | Safety in pregnancy, lactation, and children has not been established, severe renal failure, maniac phase of depression, within 14 days of MAOI administration, avoid MAOI 5 weeks after discontinuation of sertraline (concurrent use results in confusion, agitation, restlessness, GI symptoms, hyperpyretic episodes, severe convulsions, hypertensive crises, the serotonin syndrome, or death), hypersensitivity to sertraline and related drugs. |
| Side Effects | GI disturbances, dry mouth, extrapyramidal symptoms, myalgia, headache, asthenia, viral or bacterial infections, palpitation, vasodilatation, insomnia, drowsiness, dizziness, nervousness, anxiety, tremor, galactorrhoea, decreased heat rate. |
| Dosage | Initial dose: 50mg daily. Dose adjusted in the increment of 50mg over several weeks to max. of 200mg daily. Once an optimum response is attained reduce the dose to usual therapeutic dose of 50-100mg. Dose of above 150mg should not be given over 8 weeks. |
| Special Information | Less sedative than tricylics |
| Pregnancy Category | Category B2 |
| Pregnancy Category Description | Drugs which have been taken by only a small number of pregnant women and women of child-bearing age with no any established rise in the frequency of malformations or other direct or indirect detrimental effects on the foetus having been noted. Studies in animals are inadequate or lacking but available data show no evi-dence of an increased occurrence of foetal damage. Studies in animals are inadequate or lacking but available data show no evi-dence of an increased occurrence of foetal damage. |
| Drug Category | DRUGS ACTING ON CNS |
| Drug Sub-Category | Antidepressants, anxiolytics
Dosing: Adult Depression/obsessive-compulsive disorder: Oral: Initial: 50 mg/day Note: May increase daily dose, at intervals of not less than 1 week, to a maximum of 200 mg/day. If somnolence is noted, give at bedtime. Panic disorder, post-traumatic stress disorder, social anxiety disorder: Oral: Initial: 25 mg once daily; increased after 1 week to 50 mg once daily; maximum dose: 200 mg/day Premenstrual dysphoric disorder: 50 mg/day either daily throughout menstrual cycle or limited to the luteal phase of menstrual cycle, depending on physician assessment. Patients not responding to 50 mg/day may benefit from dose increases (50 mg increments per menstrual cycle) up to 150 mg/day when dosing throughout menstrual cycle or up to 100 mg day when dosing during luteal phase only. If a 100 mg/day dose has been established with luteal phase dosing, a 50 mg/day titration step for 3 days should be utilized at the beginning of each luteal phase dosing period. Dosing: Pediatric Obsessive-compulsive disorder: Oral: Children: 6-12 years: Initial: 25 mg once daily 13-17 years: Initial: 50 mg once daily May increase daily dose, at intervals of not less than 1 week, to a maximum: 200 mg/day. If somnolence is noted, give at bedtime. Dosing: Geriatric Oral: Initial: 25 mg/day in the morning; increase by 25 mg/day increments every 2-3 days if tolerated to 50-100 mg/day; additional increases may be necessary; maximum: 200 mg/day. Note: Patients with Alzheimer’s dementia-related depression may require a lower starting dosage of 12.5 mg/day, with titration intervals of 1-2 weeks, up to 150-200 mg/day maximum. Dosing: Renal Impairment Multiple-dose pharmacokinetics are unaffected by renal impairment. Hemodialysis effect: Not removed by hemodialysis Dosing: Hepatic Impairment Sertraline is extensively metabolized by the liver. Caution should be used in patients with hepatic impairment. A lower dose or less frequent dosing should be used |